Tony Hagen

Articles

Speakers Suggest Moving Newer Agents Into Earlier Lines in MM

June 13, 2021

Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.